Multiple Myeloma (MM) Clinical Trial
Official title:
MEDICI - t(11;14) and BCL2 Expression in Patients With Multiple Myeloma: Prevalence, Stability Across Lines of Therapy and Concordance Across Sample Types
Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM relapse (cancer has come back) or become non- responsive to treatment and remission gets shorter after each line of treatment. This is a study to assess t(11;14) and BCL2 expression in adult participants with newly diagnosed and relapsed/refractory (R/R) MM. Approximately 500 adult participants with newly confirmed or relapsed/refractory (R/R) multiple myeloma (MM) will be enrolled in around 15-20 countries. Participants will receive standard of care while participating in this study. No drug will be administered as a part of this study. Participants will attend regular visits during the course of the study at a hospital or clinic and will be asked to provide bone marrow and blood samples.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02265731 -
Study Evaluating Venetoclax in Subjects With Hematological Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05442580 -
CART-38 in Adult AML and MM Patients
|
Phase 1 | |
| Terminated |
NCT04178902 -
A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02920697 -
Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05908409 -
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04702425 -
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
|
Phase 1 | |
| Completed |
NCT00710528 -
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT02240537 -
Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT02203643 -
Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.
|
Phase 2 | |
| Completed |
NCT02211014 -
An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT04649073 -
Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04123418 -
A Study of WVT078 in Patients With Multiple Myeloma (MM)
|
Phase 1 | |
| Recruiting |
NCT03018405 -
A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications
|
Phase 1/Phase 2 | |
| Terminated |
NCT01663766 -
Phase I Study of Milatuzumab for Graft Versus Host Disease
|
Phase 1 | |
| Active, not recruiting |
NCT01919086 -
Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
|
Phase 2 | |
| Withdrawn |
NCT05513612 -
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
|
Phase 1 | |
| Completed |
NCT01413568 -
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT00889798 -
Tumor Registry of Lymphatic Neoplasia
|